Skip to main content
. Author manuscript; available in PMC: 2015 Aug 11.
Published in final edited form as: J Clin Exp Oncol. 2013;2(2):1000109.

Figure 8.

Figure 8

Relative cytotoxic anti-neoplastic potency of benzimidazoles against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Legends: (◆) albendazole; (▲) flubendazole; and (■) mebendazole. Chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated for 182-hours with the benzimidazole tubulin/microtubule inhibitors formulated in triplicate at gradient molar-equivalent concentrations. Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.